Futibatinib: new targeted therapy in intrahepatic cholangiocarcinoma

被引:1
作者
Khoury, Rita [1 ]
Khalife, Nadine [2 ]
Ibrahim, Rebecca [1 ]
Saleh, Khalil [1 ,3 ]
机构
[1] Gustave Roussy Canc Campus, Int Dept, Villejuif, France
[2] Gustave Roussy Canc Campus, Head & Neck Oncol Dept, Villejuif, France
[3] Gustave Roussy Canc Campus, Int Dept, 114 Rue Edouard, F-94800 Villejuif, France
关键词
Futibatinib; RLY-4008; infigratinib; pemigatinib; cholangiocarcinoma; 1ST-IN-HUMAN; INHIBITOR;
D O I
10.21037/hbsn-23-476
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:923 / 926
页数:4
相关论文
共 15 条
[1]   Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].
Abou-Alfa, Ghassan K. ;
Sahai, Vaibhav ;
Hollebecque, Antoine ;
Vaccaro, Gina ;
Melisi, Davide ;
Al-Rajabi, Raed ;
Paulson, Andrew S. ;
Borad, Mitesh J. ;
Gallinson, David ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Dotan, Efrat ;
Catenacci, Daniel, V ;
Van Cutsem, Eric ;
Ji, Tao ;
Lihou, Christine F. ;
Zhen, Huiling ;
Feliz, Luis ;
Vogel, Arndt .
LANCET ONCOLOGY, 2020, 21 (05) :671-684
[2]   Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma [J].
Arai, Yasuhito ;
Totoki, Yasushi ;
Hosoda, Fumie ;
Shirota, Tomoki ;
Hama, Natsuko ;
Nakamura, Hiromi ;
Ojima, Hidenori ;
Furuta, Koh ;
Shimada, Kazuaki ;
Okusaka, Takuji ;
Kosuge, Tomoo ;
Shibata, Tatsuhiro .
HEPATOLOGY, 2014, 59 (04) :1427-1434
[3]   Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors [J].
Bahleda, R. ;
Meric-Bernstam, F. ;
Goyal, L. ;
Tran, B. ;
He, Y. ;
Yamamiya, I ;
Benhadji, K. A. ;
Matos, I ;
Arkenau, H-T .
ANNALS OF ONCOLOGY, 2020, 31 (10) :1405-1412
[4]  
Borad Mitesh J., 2023, JOURNAL OF CLINICAL ONCOLOGY, V41
[5]   Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors [J].
Doi, Toshihiko ;
Shitara, Kohei ;
Kojima, Takashi ;
Kuboki, Yasutoshi ;
Matsubara, Nobuaki ;
Bando, Hideaki ;
Yoh, Kiyotaka ;
Naito, Yoichi ;
Hirai, Hiroshi ;
Kurokawa, Yukinori ;
Kato, Terufumi ;
Morizane, Chigusa .
CANCER SCIENCE, 2023, 114 (02) :574-585
[6]   Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma [J].
Goyal, Lipika ;
Meric-Bernstam, Funda ;
Hollebecque, Antoine ;
Valle, Juan W. ;
Morizane, Chigusa ;
Karasic, Thomas B. ;
Abrams, Thomas A. ;
Furuse, Junji ;
Kelley, Robin K. ;
Cassier, Philippe A. ;
Kluempen, Heinz-Josef ;
Chang, Heung-Moon ;
Chen, Li-Tzong ;
Tabernero, Josep ;
Oh, Do-Youn ;
Mahipal, Amit ;
Moehler, Markus ;
Mitchell, Edith P. ;
Komatsu, Yoshito ;
Masuda, Kunihiro ;
Ahn, Daniel ;
Epstein, Robert S. ;
Halim, Abdel-Baset ;
Fu, Yao ;
Salimi, Tehseen ;
Wacheck, Volker ;
He, Yaohua ;
Liu, Mei ;
Benhadji, Karim A. ;
Bridgewater, John A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (03) :228-239
[7]   TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma [J].
Goyal, Lipika ;
Shi, Lei ;
Liu, Leah Y. ;
de la Cruz, Ferran Fece ;
Lennerz, Jochen K. ;
Raghavan, Srivatsan ;
Leschiner, Ignaty ;
Elagina, Liudmila ;
Siravegna, Giulia ;
Ng, Raymond W. S. ;
Phuong Vu ;
Patra, Krushna C. ;
Saha, Supriya K. ;
Uppot, Raul N. ;
Arellano, Ron ;
Reyes, Stephanie ;
Sagara, Takeshi ;
Otsuki, Sachie ;
Nadres, Brandon ;
Shahzade, Heather A. ;
DeyGuha, Ipsita ;
Fetter, Isobel J. ;
Baiev, Islam ;
Van Seventer, Emily E. ;
Murphy, Janet E. ;
Ferrone, Cristina R. ;
Tanabe, Kenneth K. ;
Deshpande, Vikram ;
Harding, James J. ;
Yaeger, Rona ;
Kelley, Robin K. ;
Bardelli, Alberto ;
Iafrate, A. John ;
Hahn, William C. ;
Benes, Cyril H. ;
Ting, David T. ;
Hirai, Hiroshi ;
Getz, Gad ;
Juric, Dejan ;
Zhu, Andrew X. ;
Corcoran, Ryan B. ;
Bardeesy, Nabeel .
CANCER DISCOVERY, 2019, 9 (08) :1064-1079
[8]   Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma [J].
Goyal, Lipika ;
Saha, Supriya K. ;
Liu, Leah Y. ;
Siravegna, Giulia ;
Leshchiner, Ignaty ;
Ahronian, Leanne G. ;
Lennerz, Jochen K. ;
Vu, Phuong ;
Deshpande, Vikram ;
Kambadakone, Avinash ;
Mussolin, Benedetta ;
Reyes, Stephanie ;
Henderson, Laura ;
Sun, Jiaoyuan Elisabeth ;
Van Seventer, Emily E. ;
Gurski, Joseph M., Jr. ;
Baltschukat, Sabrina ;
Schacher-Engstler, Barbara ;
Barys, Louise ;
Stamm, Christelle ;
Furet, Pascal ;
Ryan, David P. ;
Stone, James R. ;
Iafrate, A. John ;
Getz, Gad ;
Porta, Diana Graus ;
Tiedt, Ralph ;
Bardelli, Alberto ;
Juric, Dejan ;
Corcoran, Ryan B. ;
Bardeesy, Nabeel ;
Zhu, Andrew X. .
CANCER DISCOVERY, 2017, 7 (03) :252-263
[9]   Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma [J].
Javle, Milind ;
Lowery, Maeve ;
Shroff, Rachna T. ;
Weiss, Karl Heinz ;
Springfeld, Christoph ;
Borad, Mitesh J. ;
Ramanathan, Ramesh K. ;
Goyal, Lipika ;
Sadeghi, Saeed ;
Macarulla, Teresa ;
El-Khoueiry, Anthony ;
Kelley, Robin Kate ;
Borbath, Ivan ;
Choo, Su Pin ;
Oh, Do-Youn ;
Philip, Philip A. ;
Chen, Li-Tzong ;
Reungwetwattana, Thanyanan ;
Van Cutsem, Eric ;
Yeh, Kun-Huei ;
Ciombor, Kristen ;
Finn, Richard S. ;
Patel, Anuradha ;
Sen, Suman ;
Porter, Dale ;
Isaacs, Randi ;
Zhu, Andrew X. ;
Abou-Alfa, Ghassan K. ;
Bekaii-Saab, Tanios .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) :276-+
[10]   Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliarytract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Kelley, Robin Kate ;
Ueno, Makoto ;
Yoo, Changhoon ;
Finn, Richard S. ;
Furuse, Junji ;
Ren, Zhenggang ;
Yau, Thomas ;
Klumpen, Heinz-Josef ;
Chan, Stephen L. ;
Ozaka, Masato ;
Verslype, Chris ;
Bouattour, Mohamed ;
Park, Joon Oh ;
Barajas, Olga ;
Pelzer, Uwe ;
Valle, Juan W. ;
Yu, Li ;
Malhotra, Usha ;
Siegel, Abby B. ;
Edeline, Julien ;
Vogel, Arndt .
LANCET, 2023, 401 (10391) :1853-1865